Forma Therapeutics Holdings Inc (OQ:FMTX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 500 Arsenal Street, Suite 100
WATERTOWN MA 02472
Tel: N/A
Website: https://ir.formatherapeutics.com
IR: See website
<
Key People
Frank D. Lee
President, Chief Executive Officer, Director
Todd E. Shegog
Chief Financial Officer, Senior Vice President
Mary Wadlinger
Chief Human Resource Officer, Senior Vice President - Corporate Affairs
David N. Cook
Senior Vice President, Chief Scientific Officer
Jeannette Potts
Senior Vice President, General Counsel & Corporate Secretary
Patrick Kelly
Senior Vice President, Chief Medical Officer
John E. Bishop
Chief Technology Officer
   
Business Overview
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).
Financial Overview
For the three months ended 31 March 2021, FormaTherapeutics Holdings Inc revenues was not reported. Netloss applicable to common stockholders totaled $36M vs.income of $9.3M. Net loss reflects Gain on Hit Discoverydivestiture decrease from $23.3M (income) to $0K, Researchand development - Balancing val increase of 9% to $24.9M(expense), Stock-based Compensation in SGA increase from$841K to $2.4M (expense).
Employees: 114 as of Apr 30, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $618.43M as of Mar 31, 2021
Annual revenue (TTM): $0.00M as of Mar 31, 2021
EBITDA (TTM): -$127.23M as of Mar 31, 2021
Net annual income (TTM): -$119.40M as of Mar 31, 2021
Free cash flow (TTM): -$103.49M as of Mar 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 47,372,658 as of Apr 30, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.